Academic Journal
Adjunctive Single-Dose Liposomal Amphotericin to Prevent Cryptococcal Meningitis in People With Human Immunodeficiency Virus (HIV)–Associated Cryptococcal Antigenemia and Low Plasma Cryptococcal Antigen (CrAg) Titers
| العنوان: | Adjunctive Single-Dose Liposomal Amphotericin to Prevent Cryptococcal Meningitis in People With Human Immunodeficiency Virus (HIV)–Associated Cryptococcal Antigenemia and Low Plasma Cryptococcal Antigen (CrAg) Titers |
|---|---|
| المؤلفون: | Meya, David B, Nalintya, Elizabeth, Skipper, Caleb P, Kirumira, Paul, Ayebare, Peruth, Naluyima, Rose, Namuli, Teopista, Turya, Fred, Walukaga, Stewart, Engen, Nicole, Hullsiek, Kathy H, Wele, Abduljewad, Dai, Biyue, Boulware, David R, Rajasingham, Radha |
| المساهمون: | National Institute of Allergy and Infectious Diseases, National Institute of Neurologic Disorders, National Center for Advancing Translational Sciences |
| المصدر: | Clinical Infectious Diseases ; ISSN 1058-4838 1537-6591 |
| بيانات النشر: | Oxford University Press (OUP) |
| سنة النشر: | 2024 |
| الوصف: | Background Cryptococcal meningitis is a leading cause of AIDS-related mortality. Cryptococcal antigen (CrAg) predicts the development of meningitis. Historically, despite standard- of-care fluconazole, 25%–30% of asymptomatic CrAg-positive persons develop breakthrough meningitis or death. We evaluated whether adding single high-dose liposomal amphotericin B to standard pre-emptive fluconazole therapy could improve meningitis-free survival. Methods Participants with human immunodeficiency virus (HIV) and asymptomatic cryptococcal antigenemia in Uganda were randomized to liposomal amphotericin B (10 mg/kg once) with fluconazole or fluconazole alone through 24 weeks. We compared 24-week, meningitis-free survival time between treatment groups. After the second interim review, the Data Safety and Monitoring Board recommended no further enrollment of participants with low plasma CrAg lateral flow assay titers (≤1:80) due to futility. Herein, we present the results of participants with low plasma CrAg titers. Results 168 participants enrolled into the ACACIA trial had low plasma CrAg titers (≤1:80). During 24 weeks of follow-up, meningitis or death occurred in 14.5% (12/83) of participants randomized to liposomal amphotericin B with fluconazole versus 10.6% (9/85) assigned to fluconazole alone (hazard ratio, 1.42; 95% CI, .60–3.36; P = .431). Adverse events were more frequent in participants assigned to the intervention versus standard-of-care (28% vs 12%; P = .011). Conclusions Among CrAg-positive persons with low titers (≤1:80), the addition of single-dose liposomal amphotericin B to fluconazole as pre-emptive therapy provided no additional clinical benefit. This trial provides supportive evidence that, in asymptomatic populations with low plasma CrAg titers, lumbar punctures are likely unnecessary as administration of meningitis treatment did not improve outcomes. Clinical Trials Registration Clinicaltrials.gov (NCT03945448). |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| DOI: | 10.1093/cid/ciae266 |
| DOI: | 10.1093/cid/ciae266/58464709/ciae266.pdf |
| الاتاحة: | http://dx.doi.org/10.1093/cid/ciae266 https://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciae266/58464709/ciae266.pdf |
| Rights: | https://academic.oup.com/pages/standard-publication-reuse-rights |
| رقم الانضمام: | edsbas.62663569 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1093/cid/ciae266 |
|---|